Rallybio Corporation RLYB on Tuesday shared results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) clinical trial of RLYB116 for complement-mediated diseases, with its initial ...

Scientists are closer to understanding how an everyday painkiller can help our bodies fight cancer. The findings may offer a complementary mechanism for preventing the development and progression of ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

A new study may have found what’s behind long COVID symptoms. Scientists say a portion of the immune system may stay activated after someone recovers from the virus. Research into what causes long ...

A recent study by researchers from Institute of Science Tokyo unveils the molecular mechanisms explaining why some "stealth" drug coatings fail to evade the immune system. Using single-molecule atomic ...

After nearly 40 years of research on how Listeria bacteria manipulate our cells and battle our immune system to cause ...